Morbidity and Mortality Weekly Report: MMWR, Volume 33U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, 1983 |
From inside the book
Results 1-5 of 100
Page 370
... Kans . 1 21 2 48 88 3 48 S. ATLANTIC Del . Md . 17 D.C. Va . 18 W. Va . N.C. S.C. Ga Fla . 18 037-8-5-68 10 17 177 348 4 134 7 73 3 2 1 1 55 . 5 28 1 27 4 22 41 12 1 5 27 +20 324 17 4 3 21 131 220 24 74 2 17 1 1 40 4 48 15 17 12 1 138 ...
... Kans . 1 21 2 48 88 3 48 S. ATLANTIC Del . Md . 17 D.C. Va . 18 W. Va . N.C. S.C. Ga Fla . 18 037-8-5-68 10 17 177 348 4 134 7 73 3 2 1 1 55 . 5 28 1 27 4 22 41 12 1 5 27 +20 324 17 4 3 21 131 220 24 74 2 17 1 1 40 4 48 15 17 12 1 138 ...
Page 371
... Kans . 16 18 39 28 1 16 326 95 28 39 5589 S. ATLANTIC 4,123 4,245 2,211 2,216 17 123 755 Del . 13 18 29 19 2 Md 255 267 260 173 10 438 DC 161 184 83 84 Va 218 297 217 214 16 126 W. Va . 10 15 74 75 5 20 NC 419 395 324 317 44 10 SC 375 ...
... Kans . 16 18 39 28 1 16 326 95 28 39 5589 S. ATLANTIC 4,123 4,245 2,211 2,216 17 123 755 Del . 13 18 29 19 2 Md 255 267 260 173 10 438 DC 161 184 83 84 Va 218 297 217 214 16 126 W. Va . 10 15 74 75 5 20 NC 419 395 324 317 44 10 SC 375 ...
Page 372
... Kans . 31 21 Kansas City , Mo. 71 43 18 279 21 13 78 50 16 99 75 58661 6 133 88 69 49 131 11 32 14 5 50 29 16 1445'2 3-13637661 33 17 21 1 2--2 22 San Diego , Calif . 130 78 22 1 San Francisco , Calif . 116 74 22 1 1 San Jose , Calif ...
... Kans . 31 21 Kansas City , Mo. 71 43 18 279 21 13 78 50 16 99 75 58661 6 133 88 69 49 131 11 32 14 5 50 29 16 1445'2 3-13637661 33 17 21 1 2--2 22 San Diego , Calif . 130 78 22 1 San Francisco , Calif . 116 74 22 1 1 San Jose , Calif ...
Page 383
... Kans . 3 3,073 3,397 S. ATLANTIC 292 30 81 12 104,094 116,413 23 83 10 Del . 3 1 1,884 2,093 3 Md . 19 7 20 11,681 14,682 7 D.C 38 7,515 7,883 7 Va 17 4 19 9,745 10,049 4 W. Va . 4 1 5 1,230 1,222 2 N.C. 6 6 16 16,302 17,059 6 S.C. 6 2 ...
... Kans . 3 3,073 3,397 S. ATLANTIC 292 30 81 12 104,094 116,413 23 83 10 Del . 3 1 1,884 2,093 3 Md . 19 7 20 11,681 14,682 7 D.C 38 7,515 7,883 7 Va 17 4 19 9,745 10,049 4 W. Va . 4 1 5 1,230 1,222 2 N.C. 6 6 16 16,302 17,059 6 S.C. 6 2 ...
Page 385
... Kans . 16 18 39 28 16 326 116 31 41 S ATLANTIC 4,255 4,342 2,311 2,316 17 147 764 Del 16 19 29 20 3 Md . 259 276 259 174 11 438 DC 166 186 84 86 Va 218 307 234 230 23 132 W. Va . 10 15 75 75 5 22 NC 428 404 340 323 55 10 S.C 385 272 280 ...
... Kans . 16 18 39 28 16 326 116 31 41 S ATLANTIC 4,255 4,342 2,311 2,316 17 147 764 Del 16 19 29 20 3 Md . 259 276 259 174 11 438 DC 166 186 84 86 Va 218 307 234 230 23 132 W. Va . 10 15 75 75 5 22 NC 428 404 340 323 55 10 S.C 385 272 280 ...
Other editions - View all
Common terms and phrases
Acquired Immunodeficiency Syndrome age group Alaska animal antibody Ariz Calif cancer Centers for Disease City Civilian clinical Colo Congenital rubella syndrome Conn cryptosporidiosis death Department of Health Disease Control E.S. CENTRAL Editorial Note Encephalitis Epidemiologic exposure Gonorrhea Guam Hawaii hemophilia Hepatitis hospital human illness immunization Immunodeficiency Syndrome AIDS increased infants infection influenza isolates Kans Legionellosis Leptospirosis lowa Malaria Mass measles MID ATLANTIC Minn MMWR Mortality Weekly Report Mumps Nebr NIOSH occurred Ohio Okla Oreg outbreak Pa.t Pac Trust Terr PACIFIC patients persons Pertussis Poliomyelitis population Primary & Secondary Psittacosis Public Health rabies Reporting Area risk RMSF Rubella specified notifiable diseases surveillance symptoms Syphilis Tenn tick-borne Total Toxic Shock syndrome Trichinosis Tuberculosis Tularemia Typhus fever U.S. Government Printing Unavailable TABLE United Upstate Utah vaccine Viral virus Wash weeks ending WN CENTRAL
Popular passages
Page 11 - National Center for Health Statistics. NCHS growth curves for children birth- 18 years. United States. Rockville, MD: National Center for Health Statistics. 1977. (Vital and health statistics. Series 1 1: Data from the National Health Survey, no.
Page 397 - Corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing rabies. Immunosuppressive agents should not be administered during postexposure therapy, unless essential for the treatment of other conditions. When rabies post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for rabies antibody...
Page 633 - ... authority to convey the warnings to the vaccinee, parent, guardian, or other responsible person of the possibility of vaccine-associated paralysis, particularly to susceptible family members and other close personal contacts. The Centers for Disease Control report that during 1972 to 1983, approximately 278.8 million OPV doses were distributed in the United States. During this same period, 87 vaccine-associated cases in apparently immunologically normal individuals were reported. Thirty-two occurred...
Page 397 - Two cases of neurologic illness resembling Guillain-Barre syndrome*'* a transient neuroparalytic illness, that resolved without sequelae in 12 weeks and a focal subacute central nervous system disorder temporally associated with HDCV, have been reported.
Page 437 - In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 1983:636-678.
Page 597 - Human cryptosporidiosis in immunocompetent and immunodeficient persons: studies of an outbreak and experimental transmission.
Page 397 - Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents (eg aspirin). Reactions after vaccination with HDCV are less common than with previously available vaccines.
Page 398 - ... Category C. Animal reproduction studies have not been conducted with IMOVAX RABIES Vaccine. It is also not known whether the product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Rabies vaccine should be given to a pregnant woman only if clearly needed. Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy...
Page 557 - Hypertension detection and follow-up program cooperative group. Fiveyear findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 392 - ... bite a person should be captured and observed for symptoms of rabies for 10 days. If symptoms do not develop, the animal may be assumed to be non-rabid. If the animal dies or is killed, its head, undamaged, should be sent promptly, under refrigeration but not frozen, to a public health laboratory. Any wild animal that bites or scratches a person should be killed at once and the head kept under refrigeration during transportation to a public health laboratory. Rubber gloves should be worn by the...